Genetic IGF1R defects: new cases expand the spectrum of clinical features.
Insulin-like growth factor 1
Insulin-like growth factor 1 receptor
Intrauterine growth retardation
Microcephaly
Short stature
Small for gestational age
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
31
01
2020
accepted:
17
04
2020
pubmed:
2
5
2020
medline:
28
8
2021
entrez:
2
5
2020
Statut:
ppublish
Résumé
We aimed to identify the phenotypic variability of IGF1R defects in a cohort of short children with normal GH secretion gathered through the last decade. Fifty children (25 girls) with short stature and a basal/stimulated growth hormone (GH) over 10 ng/ml having either a low birth weight or microcephaly were enrolled. MLPA and then Sanger sequence analysis were performed to detect IGF1R defects. The auxological and metabolic evaluation were carried out in index cases and their first degree family members whenever available. A total of seven (14%) IGF1R defects were detected. Two IGF1R deletions and five heterozygous variants (one frameshift, four missense) were identified. Three (likely) pathogenic, one VUS and one likely benign were classified by using ACMG. All children with IGF1R defects had a height < - 2.5SDS, birth weight < - 1.4SDS, and head circumference < - 1.36SDS. IGF-1 ranged from - 2.44 to 2.13 SDS. One child with a 15q terminal deletion had a normal phenotype and intelligence, whereas low IQ is a finding in a case with missense variant. Two parents who carried IGF1R mutations had diabetes mellitus, hypertension and hyperlipidemia, one of whom also had hypergonadotropic hypogonadism. We found a deletion or variant in IGF1R in 14% of short children. Birth weight, head circumference, intelligence, dysmorphic features, IGF-1 levels and even height are not consistent among patients. Additionally, metabolic and gonadal complications may appear during adulthood, suggesting that patients should be followed into adulthood to monitor for these late complications.
Identifiants
pubmed: 32356191
doi: 10.1007/s40618-020-01264-y
pii: 10.1007/s40618-020-01264-y
doi:
Substances chimiques
IGF1R protein, human
0
Receptor, IGF Type 1
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1739-1748Subventions
Organisme : Hacettepe Üniversitesi
ID : THD-2017-13561